KNSA Q2 2023 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$71M+165.0% YoY

Gross Profit

$49M68.2% margin

Operating Income

-$3M-4.4% margin

Net Income

$15M20.9% margin

EPS (Diluted)

$0.21

QoQ Revenue Growth

+47.8%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$484M

Total Liabilities

$73M

Stockholders' Equity

$412M

Cash & Equivalents

$113M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$71M	$27M	+165.0%
Gross Profit	$49M	$17M	+183.7%
Operating Income	-$3M	-$19M	+83.7%
Net Income	$15M	-$20M	+174.9%

Revenue Segments

Product

$54M76%

Collaboration

$17M24%